Introduction {#s1}
============

Genome-wide constancy and change underlies evolution and familial inheritance but remains ill-defined. An assessment of changes as the genome is passed on from one generation (meiosis) and developmental cycle (mitosis) to the next is needed. It directly contributes to the sum of genetic individuality. At present, these inquiries are difficult [@pone.0017125-Venter1], and require the development of new quantitative methods to assess genome-wide changes and their significance. This report assesses two common measures of genomic variation: copy number variations and (CNVs) and single nucleotide polymorphism (SNPs) across a generation and between monozygotic twins in two exceptional families. The results offer novel insight into meiotic and mitotic sources of variation, which results in genetic individuality between MZ twins. This individuality may account for discordance in monozygotic twins for a variety of diseases including schizophrenia.

CNVs are structural variants that are both frequent and relevant and may range in size in humans from 1 Kb to several Mb [@pone.0017125-Lee1]. Given their impact on physiology and function, CNVs have a major influence on evolution and gene expression and on normal and disease related variation [@pone.0017125-Lee1]. CNVs include duplications and deletions leading to a departure from the classic view that all autosomal genes are present in two copies, with one allele inherited from each parent. The majority of CNVs are copy number polymorphisms (CNPs), existing in a frequency that is greater than 1% and transmitted across generations. However, a small proportion of CNVs are novel events. CNVs may account for a major fraction (∼12%) of the genome, but appear to concentrate in some genomic regions depending on the sequence features [@pone.0017125-Iafrate1], [@pone.0017125-Sebat1]. Unlike CNVs, SNPs are relatively small changes, usually involving replacement of a nucleotide with another. SNPs are common and distributed across the entire human genome. Individual SNPs mark a unique genomic location, and are usually neutral in nature. In other cases, they may change amino-acids, cause protein truncation or affect expression. They are easily detected, and have been extensively exploited in genetic analysis including the cloning of disease causing genes, individual identification and establishment of genetic relatedness.

Studies on these two genome-wide variations (SNPs and CNVs) have greatly enhanced our understanding of evolution and genetic individuality. They are also helping to elucidate the cause of genetic, and genomic disorders including schizophrenia [@pone.0017125-Stankiewicz1]. A number of SNPs appear to be linked to this complex neuro-developmental disease, which has a heritability estimate of 80%. However, results of linkage studies have not been consistently reproducible [@pone.0017125-Walsh1], [@pone.0017125-Need1]. Individuals affected with schizophrenia (SCZ) have shown an elevated incidence of CNVs [@pone.0017125-Singh1] and a few rare CNVs appear to have a major effect on the development of SCZ [@pone.0017125-Grozeva1]. However, these CNVs account for only a small fraction of schizophrenia cases [@pone.0017125-Kirov1] and the challenge of identifying common genetic cause(s) of SCZ remains. The search for genes in SCZ currently relies on large number of patients and matched controls. The limited progress using these approaches emphasizes the need to pursue alternative approaches. Future studies may benefit from inclusion of two features. The first is a genome-wide comparison of the parents and their progeny affected by SCZ and the second is the assessment of genomes of monozygotic twins (that show ∼52% discordance for SCZ) [@pone.0017125-Gottesman1], [@pone.0017125-McGuffin1]. The current study reports genome-wide CNV and SNP results on two exceptional families that include monozygotic twins discordant for schizophrenia ([Figure 1](#pone-0017125-g001){ref-type="fig"}, [Table 1](#pone-0017125-t001){ref-type="table"}).

![Pedigree of two families with monozygotic twins discordant for schizophrenia.\
Members of the family one are indicated with (I-) and members of the family two are indicated with (II-). The designations included in this figure are followed in subsequent figures and tables.](pone.0017125.g001){#pone-0017125-g001}

10.1371/journal.pone.0017125.t001

###### Demography and Clinical History.

![](pone.0017125.t001){#pone-0017125-t001-1}

  Family 1                                  Family 2                                                                                                                                                                                                                                                   
  ----------------------------- --------------------------------- ----------- -------------------------------------------- ---------------------------------- -------------------------------------------------------------------------------------- -------- ---------------------------------------- ------------------------------------------------------------------
  **Age (yr.) at assessment**                  82                     74                           53                                      53                                                          N/A                                             N/A                       43                                                    43
  **Sex**                                     Male                  Female                       Female                                  Female                                                        Male                                           Female                   Female                                                Female
  **Declared Race**                       Afro-American            Caucasian                                                                                                                                                                                                                           
  **Psychiatric features**       Compulsive Personality Disorder      N/A      Schizophrenia, Paranoid Type, onset age 22   Bipolar I Disorder, onset age 52   Major depression and panic disorder for 6 months after cardiac surgery, onset age 73    N/A     Schizoaffective Disorder, onset age 27   Single episode of Major Depression, fully remitted, onset age 18

Demography and Clinical History of monozygotic (MZ) twins discordant for Schizophrenia (SCZ). Family one is indicated with (I), family two is indicated with (II). N/A = Not Applicable.

Results and Discussion {#s2}
======================

Familial Distribution of CNVs {#s2a}
-----------------------------

The number of CNVs per individual ranged from 35 to 65, with the exception of one individual who is described more fully later ([Table 2](#pone-0017125-t002){ref-type="table"}). This is similar to the number of CNVs per subject reported from most other studies that have used Affymetrix 6.0 Human SNP arrays [@pone.0017125-Ku1]. The range is also comparable with the number of CNVs found in Venter\'s genome (62) based on his complete genome sequence [@pone.0017125-Levy1]. The exception in our study was the father in family 2 (II-1-1) who was found to harbour a rare chromosome 13q deletion containing 40 CNVs at a single genomic location. Although this finding is beyond the scope of this report, it is important to note that II-1-1 underwent chemotherapy treatment and that the samples utilized in this study were obtained towards the end of that treatment. Most CNVs identified were in the range of 100 to 200 Kb, consistent with the size distribution of CNVs reported in the literature [@pone.0017125-Ku1]. The majority of CNVs observed ([Table 3](#pone-0017125-t003){ref-type="table"}) were copy number gains (78.5%) and ∼10% of the CNVs identified are not listed in the Database of Genomic Variants (<http://projects.tcag.ca/variation/>) accessed on 8.2.2010. Further, the chromosomal distribution of CNVs was comparable across individuals with the exception of the father in family 2 who had consistently higher CNVs affecting most chromosomes ([Table 4](#pone-0017125-t004){ref-type="table"}). Of the CNVs identified, \>50 per cent overlapped RefSeq genes. The identified genes are frequently associated with metabolic pathways such as starch and sucrose metabolism as well as pathways involved in the metabolism of amino acids, for example, , phenylalanine, histidine and tyrosine (*AMY2A,AMY1A,ALDH1L1,PSMC1*). Structurally, \>67% of the CNVs identified were flanked at both the 5′and 3′ end or at just the 5′ (\>7%) or 3′ (\>8%) end with a set of common repeats, represented by short interspersed nucleotide elements (SINEs), long interspersed nucleotide elements (LINEs), long terminal repeats (LTRs) and low copy repeats (LCRs) near the breakpoints. The majority of the deletion breakpoints had 1--30 bp of microhomology, whereas a small fraction of deletion breakpoints contained inserted sequences. The co-occurrence of microhomology and inserted sequence suggests that both recombination and replication based mutational mechanisms are operational in CNV generation. Recent studies have identified short DNA motifs that both determine the location of meiotic crossover hotspots and are significantly enriched at the breakpoints of recurrent non-allelic homologous recombination (NAHR) syndromes [@pone.0017125-Myers1]. We found evidence for this mechanism in a subset of the breakpoint events (data not shown). This was true for the *de novo* ([Figure 2a](#pone-0017125-g002){ref-type="fig"}) as well as inherited ([Figure 2b](#pone-0017125-g002){ref-type="fig"}) CNVs. Such sequences may represent genomic architecture that is prone to genome instability by a predisposition to genomic rearrangements via non-homologous end joining (NHEJ), template switching and/or non-allelic homologous recombination (NAHR).

![Distribution of repeat elements 1 kb upstream (5′) and 1 kb downstream (3′) of the *de novo* (2a) and *inherited* (2b) CNVs across eight individuals.\
These include LINE (blue), SINE (purple), LTR (yellow), Satellite (sky blue), simple repeats (black) and low complexity repeats (green) with numerical values on top of the bars representing percentage of that repeat.](pone.0017125.g002){#pone-0017125-g002}

10.1371/journal.pone.0017125.t002

###### Distribution of CNV among family members according to size.

![](pone.0017125.t002){#pone-0017125-t002-2}

  CNV Size                Family 1   Family 2                                                
  ---------------------- ---------- ---------- -------- -------- --------- -------- -------- --------
  **\< = 100 kb**            0          0         0        0         2        0        0        1
  **\>100 to 200 kb**        17         18        15       20       119       50       24       24
  **\>200 to 300 kb**        11         6         4        10       25        6        13       9
  **\>300 to 400 kb**        5          5         6        5        11        3        1        4
  **\>400 to 500 kb**        2          0         2        2         6        1        1        2
  **\>500 to 1000 kb**       6          2         4        7         7        2        5        2
  **\>1 to 10 Mb**           9          4         5        3         5        2        4        5
  **\>10 to 20 Mb**          5          0         0        0         0        0        0        0
  **\>20 Mb**                3          0         0        0         2        0        2        2
  **Total**                **58**     **35**    **36**   **47**   **177**   **64**   **50**   **49**

Numerical values in each cell of the table indicate how many CNVs of that particular size range were observed in that particular individual.

10.1371/journal.pone.0017125.t003

###### Identity of copy number variants across individual family members.

![](pone.0017125.t003){#pone-0017125-t003-3}

  CNVs                              Family 1   Family 2                                                
  -------------------------------- ---------- ---------- -------- -------- --------- -------- -------- --------
  **No. of Loss**                      21         6         5        6        52        11       6        4
  **No. of Gain**                      37         29        31       41       125       53       44       45
  **Novel (absent in DGV)**            1          1         0        2        42        6        1        0
  **Present in DGV**                   57         34        36       45       135       58       49       49
  **Total (for the individual)**     **58**     **35**    **36**   **47**   **177**   **64**   **50**   **49**

Frequency of CNVs which are losses (deletion) or gains (duplication) and characterization as present or absent from The Database of Genomic Variants (DGV).

10.1371/journal.pone.0017125.t004

###### Chromosome wise distribution of CNV.

![](pone.0017125.t004){#pone-0017125-t004-4}

  Chr No.      Family 1   Family 2                                                
  ----------- ---------- ---------- -------- -------- --------- -------- -------- --------
  **1**           4          2         2        2        11        2        6        6
  **2**           4          2         5        5        11        2        2        3
  **3**           1          4         2        3         7        4        4        2
  **4**           4          3         2        4         8        1        3        2
  **5**           0          0         0        0        12        0        2        1
  **6**           0          0         0        0        10        2        0        0
  **7**           2          6         3        4        10        5        3        4
  **8**           1          0         3        3         7        3        3        3
  **9**           1          1         2        3         4        4        3        4
  **10**          2          1         1        1         3        5        1        1
  **11**          3          1         2        1         5        1        2        2
  **12**          0          1         0        1         4        3        0        1
  **13**          0          0         0        0        40        1        1        0
  **14**          4          6         3        5         4        6        5        3
  **15**          4          3         1        3         2        6        6        8
  **16**          2          1         2        3         9        1        1        1
  **17**          4          1         2        3         8        2        2        1
  **18**          0          0         0        0         1        0        0        1
  **19**          0          1         0        0         7        3        2        1
  **20**          0          0         0        0         0        0        0        1
  **21**          1          2         2        3         2        3        2        1
  **22**          3          0         3        2         3        1        1        1
  **X**           18         0         1        1         9        9        1        2
  **Total**     **58**     **35**    **36**   **47**   **177**   **64**   **50**   **49**

Chromosome specific distribution of *de novo* (present in twin(s) and not in parents) and *inherited* (present in at least one parent) CNVs in family 1 and family 2.

Chr. No = Chromosome number.

Familial vs *de novo* Origin of CNVs {#s2b}
------------------------------------

A novel feature of the data included in this report is that we are able to classify observed CNVs into two groups based on their absence or presence in one of the parents. CNVs that were found in one or both twins and not seen in either parent, were classified as *de novo*. If a *de novo* CNV was present in both twins, it was considered to have originated during parental meiosis and when present in only one of the two twins, it was assumed to have originated in mitosis during development. This classification allowed us to identify 14 and 26 *de novo* CNVs in family 1 ([Table 5](#pone-0017125-t005){ref-type="table"}) and family 2 ([Table 6](#pone-0017125-t006){ref-type="table"}) respectively. The table includes genomic locations as well as individual specific break points which allow for the assessment of regions of overlap with the Database of Genomic Variants (Toronto, Ontario). Mitotic origin of CNVs was ∼3 times higher than CNVs generated during parental meiosis. Of the mitotic *de novo* CNVs identified two (loss at 14q32.11 as well as loss at 8q11.21) were specific to the schizophrenia patient in family 1 and one (gain at 19q13.41) was specific to the patient in family 2. Such results are novel in the literature. Further, it is enticing to ask the question, do the genes disturbed by CNVs contribute to the development of their disease symptoms? Although the answers to such questions are of paramount importance, the results available do not offer a direct assessment of such questions. Nonetheless, it is appropriate to entertain the discussion that the known features of these genes are or are not compatible with disturbances observed in schizophrenia, which is discussed below.

10.1371/journal.pone.0017125.t005

###### *de novo* CNVs in Family 1.

![](pone.0017125.t005){#pone-0017125-t005-5}

  Sl. No      Location     Family 1   Status         Meiosis         Mitosis   Novel   Genes (Overlapping or Nearby)      SD                                                          
  -------- -------------- ---------- -------- --------------------- --------- ------- ------------------------------- ---------- --------- --------- --------- ---------------------- ---
  1         **1p36.13**      Yes       112     16724089...16835888                                                     **Gain**             **Yes**                NBPF1, NBPF10       1
  2          **2p25.3**      Yes       152      1407209...1559511      Yes      152          1407209...1559511         **Gain**   **Yes**                               TPO            0
  3          **2p11.2**      Yes       1147    89862331...91008912     Yes     1159         89850279...91008912        **Loss**   **Yes**                                              0
  4          **4q28.3**                                                Yes      191        132801221...132992517       **Gain**             **Yes**                                    1
  5         **7q11.21**      Yes       118     64706066...64823721     Yes      118         64704377...64822216        **Loss**   **Yes**                                              1
  6          **8p23.1**      Yes       126      7847289...7973253                                                      **Loss**             **Yes**                                    1
  7          **8q11.1**      Yes       336     47045602...47381308     Yes      250         47131383...47381308        **Gain**   **Yes**                                              0
  8         **8q11.21**                                                Yes      154         48178242...48332398        **Loss**             **Yes**   **Yes**       **KIAA0146**       0
  9          **9p11.2**      Yes       569     45361389...45929992                                                     **Gain**             **Yes**                    FAM27A          1
  10         **9p13.1**                                                Yes      141         38777481...38918566        **Gain**             **Yes**                                    1
  11          **9q12**                                                 Yes      861         65412415...66273526        **Gain**             **Yes**                                    1
  12        **12p13.31**                                               Yes      196          8303317...8499801         **Gain**             **Yes**                    CLEC6A          1
  13        **14q32.11**                                               Yes      103         89780137...89883415        **Loss**             **Yes**   **Yes**   **PSMC1, C14orf102**   0
  14        **21q11.2**                                                Yes      119         13891136...14009908        **Gain**             **Yes**              ANKRD21, LOC441956    1
  15        **Xp11.23**      Yes       149     47917899...48066856     Yes      149         47917899...48066856        **Gain**   **Yes**                         SSX5, SSX1, SSX9     0

10.1371/journal.pone.0017125.t006

###### *de novo* CNVs in Family 2.

![](pone.0017125.t006){#pone-0017125-t006-6}

  Sl. No      Location     Family 2   Status          Meiosis          Mitosis   Novel   Genes (Overlapping or Nearby)      SD                                                                            
  -------- -------------- ---------- -------- ----------------------- --------- ------- ------------------------------- ---------- --------- --------- --------- ---------------------------------------- ---
  1          **1q21.1**                                                  Yes      120        143867807...143987616       **Gain**             **Yes**                            NOTCH2NL                  0
  2          **1q21.1**      Yes       104     147353175...147456930     Yes      104        147353175...147456930       **Loss**   **Yes**                                                                0
  3           **1q43**                                                   Yes      119        241230453...241349107       **Gain**             **Yes**                                                      0
  4          **3q21.2**      Yes       155     126958012...127112518                                                     **Gain**             **Yes**                                                      1
  5           **4p11**       Yes       299      48986100...49285347                                                      **Gain**             **Yes**                                                      0
  6         **5p15.33**      Yes       101        770367...871743        Yes      107           770367...877436          **Gain**   **Yes**                                      ZDHHC11                   1
  7          **5p13.3**      Yes       151      34119387...34269887                                                      **Gain**             **Yes**                                                      1
  8         **7q11.21**      Yes       202      61761008...61962936                                                      **Gain**             **Yes**                                                      0
  9         **7q11.21**      Yes       116      64588316...64704125      Yes      125         64579322...64704125        **Gain**   **Yes**                                                                1
  10          **7q35**                                                   Yes      100        142956516...143056637       **Gain**             **Yes**                       LOC441294, FAM139A             1
  11         **8p23.1**      Yes       220      12071704...12291845      Yes      220         12071704...12291845        **Gain**   **Yes**                                  FAM86B1, DEFB130              0
  12          **9p12**       Yes       2720     41465094...44184864      Yes     1901         42249132...44149779        **Gain**   **Yes**                       ANKRD20A2, ANKRD20A3, FOXD4L4, FOXD4L2   1
  13          **9q12**                                                   Yes      250         67416254...67665974        **Gain**             **Yes**                      ANKRD20A1, ANKRD20A3            1
  14        **11q13.2**      Yes       267      67239223...67505822      Yes      139         67239223...67378031        **Gain**   **Yes**                                                                1
  15        **12p13.31**                                                 Yes      189          8310909...8499801         **Gain**             **Yes**                                                      1
  16         **13q11**       Yes       208      18138676...18346383                                                      **Gain**             **Yes**                                                      1
  17        **14q11.1**      Yes       601      18072112...18672662      Yes      601         18072112...18672662        **Gain**   **Yes**                                  OR11H12, ACTBL1               1
  18        **15q11.1**                                                  Yes      106         18276329...18382609        **Gain**             **Yes**                                                      1
  19        **15q11.2**      Yes       203      19882763...20085783      Yes      221         19864583...20085783        **Gain**   **Yes**                              OR4M2, OR4N4, LOC650137           1
  20        **15q13.1**                                                  Yes      227         26808083...27035216        **Gain**             **Yes**                             APBA2                    0
  21        **15q13.2**      Yes       110      28452853...28563274                                                      **Gain**             **Yes**                            CHRFAM7A                  1
  22        **17p11.1**      Yes       199      22127012...22326425                                                      **Gain**             **Yes**                                                      0
  23        **19q13.41**     Yes       109      58847652...58957090                                                      **Gain**             **Yes**   **Yes**              **ZNF331, DPRX**              0
  24        **20q11.1**                                                  Yes      118         28147331...28264860        **Gain**             **Yes**                                                      1
  25        **21p11.2**      Yes       3480     10106540...13586186      Yes     3814         9758730...13572586         **Gain**   **Yes**                                 BAGE2, BAGE4, BAGE             0

Identity of *de novo* CNVs found in Family 1 (5a) and Family 2 (5b) and the gene regions (overlapping or nearby). *De novo* CNVs are defined as those that are present in either or both twins but not found in parents. SD displays the percentage of overlap with segmental duplications, '0' indicates no overlap between the CNV and segmental duplication and '1' indicates 90--100% overlap. The table includes genomic locations as well as twin specific breakpoints which allow for the assessment of regions of overlap with the Database of Genomic Variants (Toronto, Ontario). SI No. = Serial number. Novel indicates a CNV which is not present in The Database of Genomic Variants (DGV).

*De novo* CNVs and Schizophrenia {#s2c}
--------------------------------

The genes overlapping disease specific *de novo* CNVs in family 1 included *PSMC1* (proteasome 26S subunit, ATPase, 1) and C14orf102 (chromosome 14 open reading frame 102 gene) on 14q32.11 and *KIAA0146* on 8q11.21. *PSMC1* (MIM 602706) is an ATP-dependent protease [@pone.0017125-Tanahashi1] that may include protein ubiquitination in response to DNA damage [@pone.0017125-Huen1]. It is composed of a 20S catalytic proteasome and 2 PA700 regulatory modules and contains an AAA (ATPases associated with diverse cellular activities) domain [@pone.0017125-Tanahashi1]. The human and mouse proteins are 99% identical [@pone.0017125-Hoyle1] and may play a significant role in ubiquitin-mediated proteasomal proteolysis in the molecular pathogenesis of neurological diseases such as spinocerebellar ataxia type 7 (SCA7). Also, several studies (for review, see [@pone.0017125-Konradi1], [@pone.0017125-Mirnics1]), have indicated that the genes related to ubiquitination are altered in the brains of patients with schizophrenia. Further, this CNV also affects another gene (*C14orf102*; chromosome 14 open reading frame 102) which is conserved across phyla and highly expressed in the brain (Affymetrix GNF Expression Atlas 2 Data). The other CNV affected in this patient of family 1 represents a loss at 8q11.21, that contains the still uncharacterized gene, *KIAA0146*, which is expressed in the brain, may contain a CAG repeat and is conserved in chimpanzee, dog, cow, mouse, rat, chicken, and zebra fish. It is a transcription factor with CCAAT enhancer binding protein (CEBP) function [@pone.0017125-Lee2]. Further the gene is highly expressed in the brain and hippocampus that may implicate it in mental disorders ([www.genecards.org](http://www.genecards.org)). Although we cannot rule out a role for these three genes (*PSMC1*, *C14orf102* and *KIAA0146*) in schizophrenia, such conclusions would be premature. Only a follow up study will establish if any of the three genes directly contribute to the development of schizophrenia in the patient from family 1. A similar analysis of CNVs in family 2 has identified a 109 kb gain at 19q13.41 that is specific to the schizophrenia patient in family 2. Translocations involving 19q13 are a frequent finding in follicular adenomas of the thyroid and may represent the most frequent type of structural aberration in human epithelial tumors [@pone.0017125-Belge1]. The CNV identified in this region contains two genes; *DPRX1* and *ZNF331*. *DPRX1* (divergent-paired related homeobox) is a member of the *DPRX* homeobox gene family, contains a single conserved homeodomain and may function as a putative transcription factor. It may bind a promoter or enhancer sequence or interact with a DNA binding transcription factor and is involved in early embryonic development and cell differentiation [@pone.0017125-Booth1]. The drosophila homologue of the *DPRX1* gene (dPrx5; Drosophila peroxiredoxin 5) confers protection against oxidative stress, apoptosis and also promotes longevity [@pone.0017125-Michalak1]. The next gene, *ZNF331*(zinc finger protein 331) affected by this CNV is also involved in DNA-dependent regulation of transcription as a transcriptional repressor [@pone.0017125-Wu1]. Interestingly, it is one of the imprinted genes that exhibits monoallelic expression in a parent-of-origin specific manner [@pone.0017125-Daelemans1]. Imprinted genes are important for development and behaviour and disruption of their expression is associated with many human disorders [@pone.0017125-Meiboom1]. In conclusion the three genes affected in the schizophrenia patient in family 1 (*PSMC1*, *C14orf102*, *KIAA0146*) and the two genes affected in the patient of family 2 (*DPRX1 and ZNF331*) could not be excluded from their potential involvement in the development of schizophrenia in the two patients. If applicable, the biological systems affected in the two patients is hypothesized to be different. The patient in family one is hypothesized to have a ubiquitin-mediated proteasomal proteolysis while the patient of family 2 could have errors in regulatory mechanisms affecting gene regulation. Such conclusions must remain hypothetical until proven by independent supporting evidence.

*De novo* changes may lead to mosaicism {#s2d}
---------------------------------------

The genotypes generated by the Affymetrix 6.0 array have also allowed us to establish that ∼0.12% (1086 and 1022 in twin pair 1 and 2 respectively; 11 substitutions shared by both pairs) of the SNPs in the twins represented *de novo* substitutions, but unlike CNVs, (that primarily originated during ontogeny in mitosis) most (63--65%) originated during parental meiosis. These results suggest that DNA replication fidelity at the level of single base pairs (SNPs) vs replication forks (CNVs) is differentially exercised during meiosis and mitosis. The single base pairing is much more stringent in mitosis (evolved to produce identical daughter cells), compared to meiosis where errors can facilitate potentially beneficial variations. In contrast, CNVs which affect the phenotype may be advantageous when occurring during mitosis and selected for during development. Thus, cell type specific CNVs may play a role in growth and development, offering advantageous variability. This would mean that most individuals are mosaics [@pone.0017125-Piotrowski1]: a hypothesis that is difficult to assess and evaluate. It is likely that the ratio of mosaic cells may be maintained throughout the differentiated (ectoderm, mesoderm, endoderm, etc) tissues over the lifetime [@pone.0017125-Mkrtchyan1], [@pone.0017125-Vanneste1]; an exception being when other factors are directly influencing DNA stability. Such a mechanism may generate genomic differences and differential mosaicism in most or all individuals. If this is the case, it will complicate traditional genetic analysis that assumes stability of the genome with rare exceptions.

We have been able to establish genome-wide (CNVs and SNPs) discordance for MZ twin pairs. Also, given that the twins are discordant for schizophrenia, it is possible to assign provisional CNVs (and genes) as well as substitutions (SNPs) that may be associated with the disease status of the affected twins in family 1 and family 2 ([Table 7](#pone-0017125-t007){ref-type="table"},[8](#pone-0017125-t008){ref-type="table"}). Similarly, we identified substitutions (SNPs) that were different between the affected and unaffected member of the two sets of twins including their distribution along the chromosomes, introns and exons and the predicted effect on the gene product. Identity of *de novo* CNVs found in Family 1 ([Table 5](#pone-0017125-t005){ref-type="table"}) and Family 2 ([Table 6](#pone-0017125-t006){ref-type="table"}) and the gene regions which they overlap was reported. *De novo* CNVs are defined as those that are present in either twin but not found in parents. In the tables, SD indicates the percentage of overlap between segmental duplications and the CNVs, '0' means there is no overlap between CNV and segmental duplication and '1' means 90--100% overlap.

10.1371/journal.pone.0017125.t007

###### Inherited CNVs in Family 1.

![](pone.0017125.t007){#pone-0017125-t007-7}

  Sl. No    Location   Family 1   Status           Novel           Genes (Overlapping or Nearby)    SD                                                                                                                                                                                                                                                      
  -------- ---------- ---------- -------- ----------------------- ------------------------------- ------ ----------------------- ----- ------ ----------------------- ----- ------ ----------------------- --------------- -- ----------------------------------------------------------------------------------------------------------------------------- ---
  1         1p36.33      Yes       167        51586...218557                                                                      Yes   707       51586...758644       Yes   707       51586...758644         **Gain**                                                        OR4F5, OR4F3, OR4F16, OR4F29                                                   1
  2          1q21.1      Yes       765     147303136...148068045                Yes                734    147311699...148045353                                        Yes   577    147381253...147958358     **Gain**                                                          PPIAL4, FCGR1A, HIST2H2BF                                                    1
  3          2p11.2      Yes       338      88917155...89254935                 Yes                322     88914734...89236978    Yes   325     88917155...89242149    Yes   327     88914734...89242149      **Gain**                                                                                                                                       1
  4          2p11.1                                                             Yes                138     91017077...91154841    Yes   143     91017077...91160399    Yes   137     91017077...91154463      **Gain**                                                                                                                                       1
  5          2q21.2      Yes       236     132597824...132833718                                                                  Yes   222    132597824...132819911   Yes   222    132597824...132819911     **Gain**                                                                                                                                       1
  6          3p12.3      Yes       306      75677859...75984129                 Yes                380     75597086...75977210    Yes   182     75583442...75764996    Yes   402     75582277...75984129      **Gain**                                                                                                                                       1
  7          3q21.2                                                             Yes                132    126907150...127039328                                        Yes   185    126907150...127091652     **Gain**                                                                                                                                       1
  8          3q21.3                                                             Yes                170    131198515...131368353   Yes   166    131213377...131379054   Yes   176    131214431...131389948     **Gain**                                                                                                                                       1
  9          4p16.2                                                             Yes                196      4040542...4236511     Yes   363      3873500...4236511     Yes   366      3870638...4236511       **Gain**                                                                                                                                       0
  10          4p11       Yes       436      48849363...49285347                                                                   Yes   497     48788531...49285347    Yes   497     48788531...49285347      **Gain**                                                                                                                                       1
  11         4q35.2      Yes       232     191021837...191254119                Yes                195    191059369...191254119                                        Yes   223    191031042...191254119     **Gain**                                                          FRG1, TUBB4Q, FRG2, DUX4                                                     0
  12         7p11.1      Yes       231      57523223...57753919                 Yes                101     57640100...57741512    Yes   315     57640100...57954861    Yes   117     57640100...57757406      **Gain**                                                                                                                                       1
  13        7q11.21                                                             Yes                112     61365830...61477958                                         Yes   111     61365830...61476918      **Gain**                                                                                                                                       0
  14        7q11.21                                                             Yes                253     64320173...64573380    Yes   415     64204380...64619667    Yes   385     64204380...64589253      **Loss**                                                                    ZNF92                                                              0
  15         8p23.1      Yes       694       7209579...7903560                                                                    Yes   215      7027251...7242508     Yes   270      7021193...7291135       **Loss**         DEFB103A, DEFB103B, SPAG11B, DEFB104B, DEFB104A, DEFB106B, DEFB106A, DEFB105B, DEFB105A, DEFB107B, DEFB107A, SPAG11A, DEFB4   2
  16          9q12                                                              Yes                690     68115006...68805366    Yes   1141    68115006...69256300    Yes   694     68115006...68809437      **Gain**                                                      FOXD4L6, CBWD6, ANKRD20A4, CCDC29                                                1
  17        10q11.1      Yes       183      41972779...42155347                 Yes                105     41934430...42039743    Yes   183     41972779...42155347    Yes   239     41934430...42173117      **Gain**                                                                                                                                       1
  18        11p15.4      Yes       175       3405799...3580813                  Yes                131      3430789...3561991     Yes   139      3430789...3569305     Yes   156      3406002...3561991       **Gain**                                                                                                                                       1
  19        11q13.2      Yes       227      67239223...67466368                                                                   Yes   193     67273413...67466368                                           **Gain**                                                                                                                                       1
  20        14q11.1      Yes       1322     18138794...19460382                 Yes                1103    18072112...19175240    Yes   705     18072112...18776746    Yes   705     18072112...18776746      **Gain**                                                 OR11H12, ACTBL1, OR4Q3, OR4M1, OR4N2, OR4K5                                           0
  21        14q32.33     Yes       126     105265510...105391419                Yes                167    105100670...105268160   Yes   632    105190672...105822317   Yes   181    105149735...105331052     **Gain**                                                                                                                                       0
                         Yes       156     105413825...105569826                Yes                213    105289618...105502685   Yes   178    105827891...106005581   Yes   261    105341035...105601720     **Gain**                                                                                                                                       0
                         Yes       205     105612786...105818132                Yes                279    105508896...105788389                                        Yes   280    105612786...105892769     **Gain**                                                                                                                                       0
  22        15q11.1      Yes       471      18370252...18841457                 Yes                178     18522238...18700540    Yes   1223    18845990...20068512    Yes   562     18276329...18838423      **Gain**                                                          LOC283755, POTE15, OR4M2                                                     1
                         Yes       1177     18845990...20022565                 Yes                344     18845990...19189673                                         Yes   1078    18845990...19923712      **Gain**                                                              OR4N4, LOC650137                                                         1
                                                                                Yes                264     19303160...19566863                                                                                **Gain**                                                                                                                                       1
  23        15q11.2      Yes       189      22026287...22214843                                                                                                        Yes   174     22026287...22200408      **Gain**                                                                                                                                       1
  24        16p11.2      Yes       1217     32303108...33520394                 Yes                1297    32538757...33836128    Yes   1142    32538757...33680554    Yes   249     32538757...32787273      **Gain**                                                             LOC729355, TP53TG3                                                        1
                                                                                                                                                                       Yes   752     32910319...33662480      **Gain**                                                                                                                                       1
  25        16p11.2      Yes       250      34374795...34624994                                                                   Yes   249     34375533...34624994    Yes   249     34375533...34624994      **Gain**                                                                                                                                       1
  26        17p11.2      Yes       140      20559979...20700133                                                                                                        Yes   164     20538867...20703365      **Gain**                                                                                                                                       1
  27        17q21.31     Yes       229      41521621...41750183                                                                   Yes   123     41521621...41644356    Yes   123     41521621...41644356      **Gain**                                                              KIAA1267, LRRC37A                                                        0
  28        17q21.31     Yes       351      41756820...42107467                 Yes                296     41811739...42107467    Yes   392     41700624...42092926    Yes   302     41700624...42002447    **Gain/Loss**                                                         ARL17, LRRC37A2, NSF                                                       1
  29        21p11.2                                                             Yes                204      9758730...9962501     Yes   204      9758730...9962501     Yes   204      9758730...9962501       **Gain**                                                                    TPTE                                                               0
  30        21p11.1      Yes       3411     10106540...13517603                 Yes                3419    10106540...13525448    Yes   3419    10106540...13525448    Yes   3477    10106540...13583117      **Gain**                                                             BAGE2, BAGE4, BAGE                                                        2
  31        22q11.1      Yes       339      14435171...14774593                                                                   Yes   320     14435207...14754960    Yes   320     14435207...14754960      **Gain**                                                                   ACTBL1                                                              1
  32        22q11.21     Yes       124      20051708...20175282                                                                   Yes   136     20145854...20281562    Yes   136     20145854...20281562      **Gain**                                                                HIC2, UBE2L3                                                           1
  33        22q11.22     Yes       240      21292462...21532509                                                                   Yes   127     21327799...21454509                                           **Gain**                                                                    GGTL4                                                              0
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###### Inherited CNVs in Family 2.

![](pone.0017125.t008){#pone-0017125-t008-8}

  Sl. No    Location   Family 2   Status           Novel           Genes (Overlapping or Nearby)    SD                                                                                                                                                                      
  -------- ---------- ---------- -------- ----------------------- ------------------------------- ------ ----------------------- ----- ------- ----------------------- ----- ------- ----------------------- ---------- --------- ----------------------------------------- ---
  1         1p36.33      Yes       707        51586...758644                                                                      Yes    537       218557...755132                                            **Gain**                  OR4F5, OR4F3, OR4F16, OR4F29         1
  2         1p36.13      Yes       117      16718622...16835888                                                                   Yes    167     16718622...16885360    Yes    345     16718622...17063437    **Gain**                          NBPF1, NBPF10                1
  3          1p21.1                                                             Yes                130    103910749...104041200   Yes    127    103931691...104058426                                         **Gain**                AMY2B, AMY2A, AMY1A, AMY1C, AMY1B      1
  4          1p11.2      Yes      21680    121045307...142725034                                                                  Yes   21725   121045307...142770353   Yes   21725   121045307...142770353   **Gain**                                                       0
  5          1q23.3      Yes       121     159775403...159896554                                                                  Yes    116    159780383...159896554   Yes    121    159775403...159896554   **Loss**                     FCGR3A, FCGR2C, FCGR3B            1
  6          2p11.2      Yes       401      88925215...89326446                 Yes                759     88914227...89673147    Yes    935     88926972...89861763    Yes    450     88914734...89365010    **Gain**                                                       1
  7          2p11.1      Yes       160      91017077...91176948                                                                   Yes    268     91017077...91285520    Yes   1275     89879561...91154463    **Gain**                                                       1
  8          2q21.2      Yes       260     132593436...132853218                Yes                183    132597824...132780848                                         Yes    222    132597824...132819911   **Gain**                                                       1
  9          3p12.3      Yes       260      75583442...75843060                 Yes                226     75538978...75764996    Yes    260     75583442...75843060    Yes    182     75583442...75764996    **Gain**                                                       1
  10         3q12.2      Yes       108     101822746...101930873                                                                  Yes    102    101822746...101925168                                         **Gain**                           GPR128, TFG                 0
  11         3q21.3                                                             Yes                141    131198817...131339424   Yes    195    131194669...131389948   Yes    199    131198515...131397648   **Gain**                                                       1
  12         4p16.2      Yes       407       3870638...4278016                  Yes                180      3964803...4144453     Yes    366      3870638...4236511     Yes    357      3870638...4227503     **Gain**                              OTOP1                    0
  13         4q35.2      Yes       200     191053845...191254119                                                                  Yes    226    191028537...191254119   Yes    158    191052245...191210542   **Gain**                    FRG1, TUBB4Q, FRG2, DUX4           0
  14         7p22.1      Yes       157       6838697...6995298                                                                                                          Yes    155      6840798...6995298     **Gain**                                                       1
  15         7p11.1      Yes       117      57640100...57757406                 Yes                114     57640100...57753919    Yes    149     57604989...57753919    Yes    123     57597399...57720623    **Gain**                                                       1
  16         8p23.1      Yes       203      12415742...12618442                                                                   Yes    199     12415742...12614748    Yes    136     12415742...12551430    **Gain**                                                       1
  17        8p11.23      Yes       139      39349470...39488053                 Yes                151     39354748...39506110    Yes    133     39354748...39488053    Yes    151     39354748...39506110    **Loss**                                                       0
  18         9p11.2      Yes      21937     44336683...66273526                                                                   Yes   21015    45258754...66273526    Yes   21015    45258754...66273526    **Gain**                         FAM27A, FAM75A7               0
              9q12       Yes       861      68352238...69213455                 Yes                103     68115006...68218485    Yes   1180     68076544...69256300    Yes   1099     68115006...69213671    **Gain**                FOXD4L6, CBWD6, ANKRD20A4, CCDC29      1
                                                                                Yes                457     68352238...68809437                                                                                **Gain**                                                      
  19        10q11.1      Yes       129      41974796...42103488                 Yes                236     41934430...42170853    Yes    105     41934430...42039743    Yes    239     41934430...42173117    **Gain**                                                       1
  20        11p15.4      Yes       206       3383178...3588946                                                                    Yes    205      3376078...3580813     Yes    131      3430789...3561991     **Gain**                                                       1
  21        14q11.2                                                             Yes                186     21602854...21788783    Yes    172     21625813...21787161                                          **Loss**                                                       0
  22        14q11.2                                                             Yes                226     21804698...22030660    Yes    226     21804698...22030660                                          **Loss**                                                       0
  23        14q32.33     Yes       386     105190672...105576359                Yes                253    105345270...105597999   Yes    411    105190672...105601397   Yes    336    105265510...105601397   **Gain**                                                       0
  24        14q32.33     Yes       137     105760582...105897672                Yes                173    105645593...105818132   Yes    150    105638133...105788389   Yes    182    105640496...105822317   **Gain**                                                       0
  25        15q11.2                                                             Yes                156     18682380...18838423    Yes    183     18655531...18838423    Yes    156     18682380...18838423    **Gain**                        LOC283755, POTE15              1
                                                                                Yes                1067    18861808...19928521    Yes    572     18850029...19422452    Yes    344     18845990...19189673    **Gain**                     OR4M2, OR4N4, LOC650137           1
                                                                                                                                                                        Yes    624     19207088...19835514    **Gain**                                                       1
  26        15q25.3                                                             Yes                161     83524791...83685356    Yes    228     83524791...83752853    Yes    228     83524791...83752450    **Gain**                             AKAP12                    0
  27        15q25.3                                                             Yes                123     83784507...83907801    Yes    157     83784507...83941483    Yes    159     83790259...83949305    **Gain**                             AKAP13                    0
  28        16p11.2      Yes       118      31882658...32000323                                                                   Yes   1131     32531735...33662480    Yes   1377     32303108...33680554    **Gain**                       LOC729355, TP53TG3              1
                         Yes       294      32088275...32382422                                                                                                                                               **Gain**                                                       1
                         Yes       185      32538757...32723310                                                                                                                                               **Gain**                                                       1
                         Yes       474      32962147...33436245                                                                                                                                               **Gain**                                                       1
                         Yes       211      33451476...33662480                                                                                                                                               **Gain**                                                       1
  29        17q21.31     Yes       586      41521621...42107467                 Yes                198     41521621...41719935    Yes    586     41521621...42107467    Yes    407     41700624...42107467    **Gain**             KIAA1267, LRRC37A, ARL17, LRRC37A2, NSF   1
  30        18p11.21     Yes       1545     15262486...16807594                                                                                                         Yes    130     15218647...15348836    **Gain**                              ROCK1                    1
  31        19q13.31     Yes       116      47991257...48107552                                                                   Yes    133     47991257...48123857    Yes    235     47986218...48221228    **Loss**                     PSG1, PSG6, PSG7, PSG11           1
  32        21p11.2      Yes       204       9758730...9962501                  Yes                204      9758730...9962501     Yes    204      9758730...9962501                                           **Gain**                              TPTE                     0
  33        22q11.22     Yes       148      21300127...21448190                                                                   Yes    200     21298324...21498767    Yes    178     21298324...21476564    **Gain**                              GGTL4                    0
  34        Xp11.23      Yes       112      47917899...48029446                 Yes                269     47917899...48186708    Yes    184     47917899...48102337    Yes    257     47935225...48192383    **Gain**                     SSX5, SSX1, SSX9, SSX3            1
  35         Xq13.1      Yes       185      71869375...72054837                                                                                                         Yes    185     71869375...72054837    **Gain**   **Yes**                   DMRTC1                    1

Identity of inherited CNVs found in Family 1 (7), Family 2 (8) and the gene regions which they overlap. Inherited CNVs are those which are present in either or both parents and transmitted to either or both twins. All size is in kb. SD indicates the percentage of overlap between segmental duplications and CNVs. '0' means there is no overlap between CNV and segmental duplication, '1' means 90--100% and '2' means 50--90% overlap. Parental CNVs not transmitted to offspring were not included in [Table 5](#pone-0017125-t005){ref-type="table"}--[](#pone-0017125-t006){ref-type="table"} [](#pone-0017125-t007){ref-type="table"} [8](#pone-0017125-t008){ref-type="table"} so the total number of CNVs present in [Table 2](#pone-0017125-t002){ref-type="table"}--[](#pone-0017125-t003){ref-type="table"} [4](#pone-0017125-t004){ref-type="table"} was not same as [Table 5](#pone-0017125-t005){ref-type="table"}--[](#pone-0017125-t006){ref-type="table"} [](#pone-0017125-t007){ref-type="table"} [8](#pone-0017125-t008){ref-type="table"}. The table includes genomic locations as well as individual specific break points which allow for the assessment of regions of overlap with the Database of Genomic Variants (Toronto, Ontario). SI No. = Serial number. Novel indicates a CNV which is not present in The Database of Genomic Variants (DGV).

We also analyzed genes that overlapped *de novo* CNVs (gains and losses) in order to assess their potential effect on physiology and function starting with GO ontology annotation (<http://www.geneontology.org>). Interestingly, the majority of genes belonged to transcription, DNA replication, transport, and cell signalling pathways, including 'binding' or 'catalytic' functions. A number of these genes are expressed in the brain, some with potential to affect neurophysiology, neurodevelopment and function and a set of them are known to show altered expression in schizophrenia ([www.schizophreniaforum.org](http://www.schizophreniaforum.org)). Also of significance is the observation that the FAM19A5 protein encoded by the *FAM19A5* gene (22q13.32) belongs to the TAFA protein family which are predominantly expressed in the brain, and are postulated to function as brain-specific chemokines or neurokines, that act as regulators of immune and nervous cells [@pone.0017125-Schwartz1]. This finding adds to the existing speculation about the role of the Major Histocompatability Loci (MHC) and infection in SCZ. Functional analysis of this gene and upstream regulatory elements for characteristic patterns of nucleosome occupancy changes associated with enhancers could yield novel insights into the role of this gene in psychiatric disorders. IPA analysis of gene networks of CNVs and SNPs converged on cell cycle, cellular growth and proliferation. Genes involved in genetic disorders such as hematological disease, immunological, inflammatory and developmental disorders were overrepresented. These results support the hypothesis that schizophrenia is a "developmental disorder" at the molecular level. Interestingly, a recent co-expression network analysis of microarray-based brain gene expression data revealed perturbations in developmental processes in schizophrenia [@pone.0017125-Torkamani1]. However, given that these results are based on only two twin pairs, and schizophrenia is highly heterogeneous, the results on disease causations cannot be generalized. Also, we have offered other explanations for twin discordance that may involve epigenetic changes [@pone.0017125-Singh2].

It is not surprising that genomic studies have begun to use monozygotic twins. In fact a number of them have identified copy number variations [@pone.0017125-Bruder1] and epigenetic [@pone.0017125-Ollikainen1]--[@pone.0017125-Kaminsky1] differences between them; an exception to these results is a recent study by Baranzini *et al* [@pone.0017125-Baranzini1]. They studied three pairs of monozygotic twins discordant for Multiple Sclerosis (MS) and found no difference that could account for the disease causation. The results may be viewed as not surprising for a number of reasons. First, MS is known to have significant environmental components including sunlight and viruses, among others, [@pone.0017125-Milo1] and the concordance rate in monozygotic twins is only ∼30%. Second, they assessed the CD4+ lymphocytes only that may or may not represent the causative cell type. Also, they sequenced the genome of CD4+ cells from a single pair corresponding to 21.7 and 22.5-fold coverage representing 99.6% and 99.5% of the NCBI human reference genome, which may or may not be effective. Only additional genomic and epigenomic studies on MZ twins will offer insights into the dynamics of genomic stability and change, that forms the focus of this report.

In summary, the present study adds to the recent effort in human genetics to define the phenomenon of constancy and change using inheritance and origin of genome-wide CNVs and SNPs. The results demonstrate that CNVs often result from mitosis during early development facilitated by flanking repeats. They may lead to CNV differences among different tissue and make most individuals mosaics. The described approach expands the search for disease related genetic changes, indicates the time of their occurrence and begins to interrogate the mechanisms involved.

Materials and Methods {#s3}
=====================

This research was approved by the Committee on Research Involving Human Subjects at the University of Western Ontario. The families and patients were identified, recruited and clinically assessed by Dr. Richard O\'Reilly (Psychiatrist) and all participants ([Figure 1](#pone-0017125-g001){ref-type="fig"}) gave informed consent and provided blood and buccal cells for this research. All subjects were interviewed using the Structured Clinical Interview for DSM IV and the SCID II (for personality disorders) and their medical records collected and reviewed. Diagnoses and demographic information are listed in [Table 1](#pone-0017125-t001){ref-type="table"}. DNA was extracted from the collected white blood cells using the perfect pure DNA blood kit (5prime.com) following the manufacturer\'s protocol. Subsequent microarray analysis was performed using the Affymetrix Genome-Wide Human SNP Array 6.0 at the London Regional Genomics Centre (LRGC) following manufacturer\'s protocol and stringent quality control measures. Briefly, 5 µg of genomic DNA was labelled and hybridized to Affymetrix SNP 6.0 arrays. CNVs called by both Affymetrix Genotyping Console 4.0 and Partek® Genotyping Suite™ software suites were retained for analysis. In both cases, the CNVs were identified by continuity of markers on a segment. Two CNVs that overlapped by \>50% in the two methods of data analysis were given the same identity. Every measure was undertaken to avoid inclusion of false positives including correction for segmental duplications. We found evidence of CNVs associated with segmental duplications which agrees with previous studies [@pone.0017125-Hastings1]. The CNVs identified were further assessed by comparison to the Database of Genomic Variants (<http://projects.tcag.ca/variation/>) and annotated with gene symbols by importing the annotation file from the UCSC genome browser (NCBI36/hg 18). A CNV that was present in both members of the twin pair and not in either of their two parents was considered to be meiotic *de novo* (originated during gamete formation), while a CNV that was present in one of the two twins and not present in either parent was considered to be mitotic *de novo* (originated during development). Further, a CNV present in the SCZ affected twin only (as compared to the two parents and unaffected member of the pair or the database) was classified as "provisional *de novo* CNV" for this disease. Novel CNVs discovered in this study were validated for predicted CNVs by Real Time PCR analysis with an internal control (RNAseP gene) using TaqMan detection chemistry and the ABI Prism 7300 Sequence Detection System (Applied Biosystems, <http://www.appliedbiosystems.org>). The copy number of the test locus in each case was defined as 2T^−ΔΔC^ where ΔCT is the difference in threshold cycle number for the test and reference loci.

Additional CNV analysis focused on two aspects. The first deals with identification of putative repeat elements in the flanking regions of CNVs; within a 1 kb region upstream and downstream of the CNV breakpoint which could promote breakage, deletion and duplication. The identification of repeat elements was carried out using repeat masker (<http://www.repeatmasker.org/>). Secondly, a probable mechanism associated with sequence-specific susceptibility to CNVs was queried. This data was used to test models related to the origin of CNVs. Previously reported candidates for CNV mechanisms include Non-Allelic Homologous Recombination (NAHR), Non-Homologous End Joining (NHEJ), Fork Stalling and Template Switching (FoSTeS) and Microhomology-Mediated Break-Induced Replication (MMBIR) [@pone.0017125-Zhang1]. The second line of investigation involved functional characterization of genes by matching of the identified genes with the Schizophrenia Gene Database (<http://www.schizophreniaforum.org/res/sczgene/default.asp>) as well as their assessment by GO ontology (<http://www.geneontology.org/>). The genes identified were also subjected to IPA analysis ([www.ingenuity.com](http://www.ingenuity.com)) that identified the nature of gene interactions and the pathways involved.

The use of Affymetrix 6.0 Human SNP array also allowed us to assess the transmission of a total of 909622 SNPs that are contained on the array. It allowed us to identify SNPs in the twins that were not present in either of the two parents; considered to be *de novo*. The origin of the *de novo* SNPs was assumed to be parental meiosis if both twins carried the novel nucleotide. In contrast, the origin of the *de novo* SNPs was assumed to be somatic development (mitosis) if only one of the two twins carried the novel nucleotide. We were able to assign novel substitutions to different categories including their potential effect on the gene and gene product, as well as pathways that may be affected.

We thank members of the two families who participated in this research.
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